August 16, 2013
Multi-Treatment Platform Offers Multi-Billion Dollar Opportunity for Nuvilex
On the heels of closing the acquisition of licenses representing the exclusive rights to the live-cell encapsulation platform for pancreatic and other cancers, Nuvilex, Inc. (OTCQB – NVLX) announced via a shareholder update that it is in the process of securing similar rights for diabetes treatment as well. Funding has been committed and the closing is expected no later than the end of October 2013.
Given the alarming statistics and the fact that there is a real unmet need, this is tremendous news for the Company and its shareholders.
Diabetes is a major health issue in the United States and other industrialized nations. According to the American Diabetes Association, nearly 24 million people in the U.S., or 8% of the population, have either Type I or Type II diabetes. Estimates indicate that nearly 25% of people with the disease are unaware that they have it. Type I is commonly diagnosed in children, where the body does not produce insulin. Type II is developed in adults and is the condition where “insulin resistance” develops (cells of the body do not use insulin effectively), and is particularly tied to obesity or bad diet habits. The number of patients diagnosed with Type II diabetes is growing at an alarming rate. According to the CDC, the rates of Type 2 Diabetes in the US have increased from 4.8 per 1,000 in 1995-1997 to 9.1 per 1,000 in 2005-2007, a 90% increase.
This is why the estimated annual sales of diabetes drugs in the U.S. are $22 billion.
Clinicians and physicians have long known about the undefined correlation between the litany of health problems associated with diabetes and the link to pancreatic cancer, which is one of the reasons why the Nuvilex deal makes so much sense.
Several research studies have found that about 80% of patients who have pancreatic cancer also have glucose intolerance issues or diabetes. Another study found that people diagnosed with diabetes after age 50 are eight times more likely to develop pancreatic cancer compared with the general population. While there is not a definitive cause-effect relationship, two theories are prevalent in the medical community. One, pancreatic cancer may result in diabetes and two, the conditions that cause diabetes may cause abnormal growth in the pancreas and lead to subsequent pancreatic cancer.
Clearly, Nuvilex plans to take advantage of the soon-to-be acquired early-stage diabetes treatment technology and research combined with its advanced pancreatic cancer trials data to leverage its platform live-cell encapsulation technology to treat both diseases. Moreover, considering that the animal study data to date indicates that the need for insulin therapy could be eliminated through the use of its live-cell encapsulation-based technology, Nuvilex is moving yet another step closer toward introducing a game-changing multi-disease treatment platform that is potentially worth billions in annual sales. As a result, Nuvilex is a must-own stock.
For more information, refer to our previous NVLX Reports, Updates and Hot Topics by visiting www.GoldmanResearch.com
You Might Also Like
Senior Analyst: Robert Goldman
The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, or other firms. Goldman Small Cap Research relied solely upon information provided by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such information and the opinions expressed are subject to change without notice. A Goldman Small Cap Research report, update, article, or note is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed.
This publication does not take into account the investment objectives, financial situation, or particular needs of any particular person. This report does not provide all information material to an investor’s decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither Goldman Small Cap Research, nor its parent, is registered as a securities broker-dealer or an investment adviser with FINRA, the U.S. Securities and Exchange Commission or with any state securities regulatory authority.
ALL INFORMATION IN THIS REPORT IS PROVIDED “AS IS” WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.